VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemesMarketEarningsCompareWatchlistInsider
ARCTArcturus Therapeutics Holdings Inc.
$7.53$214M
Research
Overview
Valuation
ValuationTargetsPrice
Financials
RevenueEarningsP/ERatiosDividend
Ownership
Holders
Tools
Total ReturnDCA Calculator
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

Follow VCP Scanner on XFollow VCP Scanner on LinkedIn
© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksARCTEarnings History

ARCT logoArcturus Therapeutics Holdings Inc. (ARCT) Earnings History

Net Loss

15 years of earnings data (2011–2025) · Currently unprofitable on a TTM basis

TTM Net Income
-$79M
● Net Loss
TTM EPS (Diluted)
$-2.77
Per share, diluted
YoY EPS Growth
+20.0%
Excellent
Net Margin
-97.9%
After-tax profitability
EPS Growth Rate (CAGR)
1YN/A
3YN/A
5YN/A
10YN/A
Operating Margin-111.5%
Gross Margin95.5%
Return on Equity-28.9%
Return on Assets-21.4%
Record Annual Net Income$9MFY2022
Record Quarterly EPS$4.33Q4 2022
Consecutive Profitable Years0years
Q1 2026
Net Income-$27M
EPS (Diluted)$-0.95
YoY Growth+20.0%Excellent
QoQ Growth+7.3%Solid

Loading earnings history...

Arcturus Therapeutics Holdings Inc. (ARCT) Earnings Overview

As of June 22, 2026, Arcturus Therapeutics Holdings Inc. (ARCT) reported trailing twelve-month net income of -$79M, reflecting +20.0% year-over-year growth. The company earned $-2.77 per diluted share over the past four quarters, with a net profit margin of -97.9%.

Looking at the long-term picture, ARCT's historical earnings data spans multiple years. The company achieved its highest annual net income of $9M in fiscal 2022.

Arcturus Therapeutics Holdings Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →

Compared to peers including MRNA (-$3.19B net income, -145.2% margin), BNTX (-$1.13B net income, -39.6% margin), NTLA (-$395M net income, -609.9% margin), ARCT has outperformed on profitability metrics. Compare ARCT vs MRNA →

ARCT Earnings vs Peers

Earnings metrics vs comparable public companies

CompanyTTM Net IncomeTTM EPSNet MarginROEYoY GrowthCompare
ARCT logoARCTCurrent
-$79M$-2.77-97.9%-28.9%+20.0%—
MRNA logoMRNA
-$3.2B$-8.09-145.2%-28.9%+21.7%
BNTX logoBNTX
-$1.1B$-4.62-39.6%-5.7%-62.8%
NTLA logoNTLA
-$395M$-3.33-609.9%-53.5%+27.4%
CRSP logoCRSP
-$569M$-5.92-16569.8%-30.2%-49.1%
BEAM logoBEAM
-$65M$-0.63-57.2%-8.1%+82.3%
Best in group
Lowest in group

ARCT Historical Earnings Data (2011–2025)

15 years
Fiscal Year Net Income YoY % Operating Income EPS (Diluted) Net Margin Op. Margin
2025-$66M+18.7%-$75M$-2.40-97.9%-111.5%
2024-$81M-172.3%-$96M$-3.00-58.5%-69.1%
2023-$30M-417.9%-$78M$-1.12-18.8%-49.6%
2022$9M+104.6%$12M$0.354.5%5.9%
2021-$204M-182.3%-$203M$-7.74-1648.0%-1641.3%
2020-$72M-177.6%-$72M$-3.55-756.3%-749.8%
2019-$26M-19.3%-$26M$-2.13-125.0%-122.7%
2018-$22M-99.8%-$22M$-2.16-138.3%-138.5%
2017-$11M+55.7%-$10M$-3.53-83.9%-80.7%
2016-$25M-26.5%-$25M$-6.25-120.7%-123.5%
2015-$19M+40.8%-$20M$-6.29-316.9%-320.9%
2014-$33M-211.3%-$33M$-16.81--
2013-$11M-568.0%-$10M$-7.25--
2012-$2M+59.8%-$2M$-0.99--
2011-$4M--$4M$-2.47--

Download Data

Export ARCT earnings history in CSV or JSON format

Free sign-in required to download data

Consensus-Based Analysis Tools

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

15+ years return with dividends reinvested.

Calculate

DCA Calculator

See how regular investing compounds over time.

Run Numbers

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

ARCT — Frequently Asked Questions

Quick answers to the most common questions about buying ARCT stock.

What is ARCT earnings per share (EPS)?

ARCT trailing twelve-month (TTM) diluted EPS is $-2.77, reflecting +20.0% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2011 to 2025 is available in the table on this page.

What is Arcturus Therapeutics Holdings Inc.'s net income?

Arcturus Therapeutics Holdings Inc. (ARCT) trailing twelve-month net income is $-79M as of 2025. Earnings grew +20.0% year-over-year.

Is ARCT profitable?

ARCT is not currently profitable on a TTM basis, reporting a net loss of $-79M. Net margin is -97.9%. Investors should monitor for a return to profitability.

What is ARCT's earnings growth rate?

ARCT compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2011 to 2025.

What are ARCT's profit margins?

Arcturus Therapeutics Holdings Inc. net profit margin is -97.9%, operating margin is -111.5%, and gross margin is +95.5%. Below-average margins reflect competitive or cost pressures. Return on Equity is -28.9%.

Is ARCT growing earnings?

Yes, ARCT earnings are accelerating — EPS growth of +20.0% exceeds the 5-year CAGR of N/A. TTM net income reached $-79M. Earnings momentum is strengthening.

What was ARCT's best earnings year?

Arcturus Therapeutics Holdings Inc.'s highest annual net income on record is $9M, achieved in fiscal year 2022. Earnings history on this page spans 2011 to 2025 and includes all annual and quarterly figures.

What were ARCT's earnings last quarter?

ARCT's most recent reported quarter was Q1 2026. Net income was $-27M with diluted EPS of $-0.95. For a full breakdown of all quarters, see the quarterly earnings table on this page.

ARCT Earnings Over Time (2011–2025)

Net income & EPS — annual and quarterly view